Multiple Myeloma

CancerNetwork® spoke with Rafael Fonseca, MD, about the rationale for a simulation using real-world data sets to compare the utility of daratumumab-containing regimens as either frontline or second-line therapy.

Luciano Costa, MD, PhD, spoke about how the results in the final primary analysis of the MASTER trial with daratumumab, carfilzomib, lenalidomide, and dexamethasone in multiple myeloma were not what he expected.

As the year 2021 comes to a close, CancerNetwork® sat down with Yael Cohen, MD, to discuss practice-changing clinical research in multiple myeloma that read out in 2021 and potential FDA updates that may take place in 2022.

Nina Shah, MD, discusses the current treatment options for treating patients with transplant-ineligible multiple myeloma.

Nina Shah, MD, on the current treatment options for treating patients with transplant-eligible multiple myeloma.

Nina Shah, MD, discusses the biggest news from the FDA for multiple myeloma in the past year.

Patients with triple-class relapsed/refractory multiple myeloma treated with ciltacabtagene autoleucel saw a greater survival benefit over physician's choice of treatment.

Most subgroups of patients with relapsed or refractory, heavily pretreated multiple myeloma showed durable responses at the 2-year follow-up to the CARTITUDE-1 trial.

Patients with heavily pretreated relapsed/refractory multiple myeloma achieved promising benefit in terms of cytokine release syndrome mitigation via double cycle 1 step-up dosing for cevostamab.

Deep responses were seen with single infusion ciltacabtagene autoleucel for heavily pretreated patients with multiple myeloma who were refractory to lenalidomide.

When asked about abstracts he thinks have the greatest potential to impact the standard of care in myeloma, Rafael Fonseca, MD, looked to emerging cellular therapies, specifically ciltacabtagene autoleucel for the treatment of heavily pretreated disease.

Patients with relapsed/refractory multiple myeloma continue to experience robust and durable benefit from treatment with ciltacabtagene autoleucel.

Patients with relapsed/refractory t(11;14) multiple myeloma appeared to benefit from treatment with venetoclax at a dose of 400 mg or 800 mg plus daratumumab/dexamethasone.

Luciano Costa, MD, PhD, spoke about the primary end point analysis for the MASTER trial examining daratumumab, carfilzomib, lenalidomide, and dexamethasone in multiple myeloma.

Daratumumab plus lenalidomide, bortezomib, and dexamethasone followed by transplant continues to show superior efficacy vs triplet therapy alone at a 2-year follow-up to the GRIFFIN trial.

A post hoc analysis showed that a dose reduction of selinexor yielded higher safety and efficacy for patients with multiple myeloma.

Patients with newly diagnosed, transplant-eligible multiple myeloma continue to experience robust and durable responses to treatment with daratumumab, lenalidomide, bortezomib, and dexamethasone plus autologous stem cell transplant followed by daratumumab plus lenalidomide maintenance.

Ciltacabtagene autoleucel as a single infusion led to early, durable responses, and demonstrated positive minimal residual disease negativity for patients with multiple myeloma who had early clinical relapse.

In an assessment of 2 patient cases of relapsed or refractory multiple myeloma with translocations in t(11;14), selinexor plus venetoclax was safe and efficacious.

The treatment combination of selinexor plus pomalidomide and dexamethasone at the recommended phase 2 dose produced more durable and deep responses than the lesser selinexor dose for relapsed or refractory multiple myeloma.

Data for ciltacabtagene autoleucel from CARTITUDE-1 show that use in the setting of heavily pretreated multiple myeloma bests standard-of-care treatments.

Thomas G. Martin, MD, spoke about the updated results of the CARTITUDE-1 study examining ciltacabtagene autoleucel in relapsed or refractory multiple myeloma.

Induction and consolidation with daratumumab, ixazomib, lenalidomide, and dexamethasone was able to induce minimal residual disease in a subset of patients with transplant-eligible newly diagnosed multiple myeloma and standard-risk disease.

Among patients with newly diagnosed multiple myeloma, 80% of a study cohort reached MRD negativity following treatment with daratumumab, carfilzomib, lenalidomide, and dexamethasone.

Weekly selinexor combined with bortezomib and dexamethasone appears to be a promising option in patients with high-risk multiple myeloma.

A population of patients with relapsed/refractory multiple myeloma appeared to benefit from treatment with selinexor plus daratumumab, bortezomib, and dexamethasone

Adding isatuximab to lenalidomide, bortezomib, and dexamethasone demonstrated a superior minimal residual disease rate in patients with transplant-eligible newly diagnosed multiple myeloma.

The combination of daratumumab with bortezomib, cyclophosphamide, and dexamethasone continued to improve hematologic and organ responses after 18 months of follow-up.

Findings from the phase 1b TRIMM-2 study indicated that patients with relapsed/refractory multiple myeloma experienced manageable toxicities and promising responses to treatment with talquetamab and daratumumab.

Research presented at the 63rd ASH Annual Meeting and Exposition found significantly higher MRD-negativity and sustained MRD-negativity rates among patients with transplant-eligible newly diagnosed multiple myeloma receiving D-VTd over VTd alone.